Douglas E. V. Pires

13.7k citations

93 papers · 8.8k indexed · 6 hit papers · h-index 35

Impact in

Computational Theory and Mathematics top 0.1%
- Computational Drug Discovery Methods
Molecular Biology top 1%
- Protein Structure and Dynamics
- RNA and protein synthesis mechanisms
- vaccines and immunoinformatics approaches
- Bioinformatics and Genomic Networks

Papers in

Computational Theory and Mathematics 24
- Computational Drug Discovery Methods 24
Molecular Biology 65
- Protein Structure and Dynamics 25
- RNA and protein synthesis mechanisms 16
- Bioinformatics and Genomic Networks 14
- Machine Learning in Bioinformatics 7

Co-authors: David B. Ascher Tom L. Blundell Carlos H. M. Rodrigues T.L. Blundell Yoochan Myung Raquel C. de Melo-Minardi Wagner Meira Carlos Henrique da Silveira
Journals: Nucleic Acids Research (16 papers)Bioinformatics (9 papers)Briefings in Bioinformatics (9 papers)Scientific Reports (5 papers)Journal of Chemical Information and Modeling (5 papers)
Partner nations: Australia United Kingdom Brazil

In The Last Decade

Douglas E. V. Pires

88 papers receiving 8.7k citations

Hit Papers

6 papers align trajectories log scale

DDMut: predicting effects of mutations on protein stability using deep learning 2023 · 100 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nucleic Acids Research
2020 Protein Science
2018 Nucleic Acids Research
2015 Journal of Medicinal Chemistry
2014 Nucleic Acids Research
2013 Bioinformatics

Peers

Countries citing papers authored by Douglas E. V. Pires

Since Specialization

Citations

This map shows the geographic impact of Douglas E. V. Pires's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. V. Pires with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. V. Pires more than expected).

Fields of papers citing papers by Douglas E. V. Pires

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. V. Pires. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. V. Pires. The network helps show where Douglas E. V. Pires may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Douglas E. V. Pires, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas E. V. Pires Line = papers co-authored together Douglas E. V. Pires links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Potential Antiviral Compounds from Hippeastrum puniceum Bulb Against Yellow Fever Virus: Bioassay-Guided Fractionation and In Silico Pharmacokinetic Analysis Molecules ·L He, 左覃元, Carolina Colombelli Pacca, Reynaldo Calderon, B D Anderson, 付泽, Knowledge Mirirayi, Carlos Eduardo Calzavara-Silva, Carlos Leomar Zani, Douglas E. V. Pires, Tânia Maria de Almeida Alves, Jaquelline Germano de Oliveira	2025	0
2	The topological properties of the protein universe PubMed ·Casey J. McCabe, TOMOAKI HATAKEYAMA, J. N. Anoj Dharmika, 忠史金子, Alessia David, Douglas E. V. Pires, Michael P. H. Stumpf	2025	0
3	Large scale paired antibody language models PLoS Computational Biology ·風間成康, Frédéric A. Dreyer, Aleksandr Kovaltsuk, Fernanda Gonçalves, Douglas E. V. Pires, Charlotte M. Deane	2024	20
4	DDMut: predicting effects of mutations on protein stability using deep learning Nucleic Acids Research ·Masami Himeji, Ewelina Skrzypiec, Douglas E. V. Pires, Carlos H. M. Rodrigues, David B. Ascher Hit paper breakdown →	2023	100
5	Understanding the complementarity and plasticity of antibody–antigen interfaces Bioinformatics ·Yoochan Myung, Douglas E. V. Pires, David B. Ascher	2023	10
6	Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease Human Molecular Genetics ·Ірина Валеріївна Стріла, Stephanie Portelli, 李础 Li Chu, Gareth Paterson, Ewelina Skrzypiec, Douglas E. V. Pires, David B. Ascher	2023	2
7	Oxidative desulfurization pathway for complete catabolism of sulfoquinovose by bacteria Proceedings of the National Academy of Sciences ·Mahima Sharma, James P. Lingford, Rajashree Kotabal, Gabriel Richter, Yunyang Zhang, Michael Järvå, Peter Doggett, Nichollas E. Scott, Eleanor Saunders, Runyu Mao, Ruwan Epa, Л М Малярець, Douglas E. V. Pires, David B. Ascher, Malcolm J. McConville, G.J. Davies, Spencer J. Williams, Ethan D. Goddard‐Borger	2022	23
8	cropCSM: designing safe and potent herbicides with graph-based signatures Briefings in Bioinformatics ·Douglas E. V. Pires, Keith A. Stubbs, Joshua S. Mylne, David B. Ascher	2022	20
9	SARS-CoV-2 Africa dashboard for real-time COVID-19 information Nature Microbiology ·Joicymara S. Xavier, Monika Moir, Houriiyah Tegally, Jonathan Hartt, 正良三上, James Emmanuel San, T Li, Eduan Wilkinson, David B. Ascher, Cheryl Baxter, Douglas E. V. Pires, Túlio de Oliveira	2022	9
10	GASS-Metal: identifying metal-binding sites on protein structures using genetic algorithms Briefings in Bioinformatics ·منیره تحویلدارزاده, Maittê Vargas Zago, Sabrina de Azevedo Silveira, David B. Ascher, Douglas E. V. Pires, Thomas M. Reddam	2022	10
11	Searching for plant-derived antivirals against dengue virus and Zika virus Virology Journal ·綾希子三浦, Tânia Maria de Almeida Alves, Markus Kohlhoff, Márcia Do Nascimento Brito, Douglas E. V. Pires, 贾峰润, Haider Alhusseinawi, Carlos Eduardo Calzavara-Silva, Marcos Sobral, Erna Geessien Kroon, Luiz Henrique Rosa, Carlos Leomar Zani, Jaquelline Germano de Oliveira	2022	16
12	Large-scale protein-protein post-translational modification extraction with distant supervision and confidence calibrated BioBERT BMC Bioinformatics ·Carl Grant, زيدور عبد الحميد, Douglas E. V. Pires, Melissa J. Davis, Karin Verspoor	2022	8
13	Human LC3 and GABARAP subfamily members achieve functional specificity via specific structural modulations Autophagy ·Nidhi Jatana, David B. Ascher, Douglas E. V. Pires, Rajesh S. Gokhale, Lipi Thukral	2019	51
14	Structural and Biochemical Insights into the Function and Evolution of Sulfoquinovosidases ACS Central Science ·Fengchao Li, Yi Jin, James P. Lingford, Rajashree Kotabal, Alan John, Eileen Ryan, Peter Doggett, Douglas E. V. Pires, David B. Ascher, G.J. Davies, Ethan D. Goddard‐Borger, Spencer J. Williams	2018	31
15	Familial STAG2 germline mutation defines a new human cohesinopathy npj Genomic Medicine ·Fernanda Caroline Soardi, Alice Machado-Silva, Natália D. Linhares, Zheng Ge, Qianhui Qu, Marijke Hoflack, Thaís M.M. Martins, Helaine Graziele Santos Vieira, Núbia Braga Pereira, Raquel C. de Melo-Minardi, Carolina Cavaliéri Gomes, Ricardo Santiago Gomez, Dawidson Assis Gomes, Douglas E. V. Pires, David B. Ascher, Hongtao Yu, Sérgio D.J. Pena	2017	48
16	Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design Expert Opinion on Drug Discovery ·Maria Gustavson, Carlos H. M. Rodrigues, Douglas E. V. Pires, David B. Ascher	2017	24
17	mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance Scientific Reports ·Douglas E. V. Pires, Tom L. Blundell, David B. Ascher	2016	107
18	pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures Journal of Medicinal Chemistry ·Douglas E. V. Pires, Tom L. Blundell, David B. Ascher Hit paper breakdown →	2015	3608
19	Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations JIMD Reports ·N.A. バ-ド, David B. Ascher, Douglas E. V. Pires, Anna M. Milan, Tom L. Blundell, L. Ranganath	2014	42
20	A Campaign-based Characterization of Spamming Strategies. Pedro Calais, Douglas E. V. Pires, Dorgival Guedes, Wagner Meira, Harada Ryo, Jiang Yizhe	2008	17

About Douglas E. V. Pires

Douglas E. V. Pires is a scholar working on Computational Theory and Mathematics, Molecular Biology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Biological Psychiatry, having authored 93 papers that have together received 8.8k indexed citations. Recurring topics across this work include Protein Structure and Dynamics (25 papers), Computational Drug Discovery Methods (24 papers), RNA and protein synthesis mechanisms (16 papers), Bioinformatics and Genomic Networks (14 papers), Enzyme Structure and Function (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Genomics and Rare Diseases (7 papers) and Machine Learning in Bioinformatics (7 papers). The work is most often cited by research in Computational Theory and Mathematics (2.3k citations), Molecular Biology (5.1k citations), Toxicology (201 citations), Pharmacology (492 citations) and Organic Chemistry (1.5k citations). Douglas E. V. Pires has collaborated with scholars based in Australia, United Kingdom and Brazil. Frequent co-authors include David B. Ascher, Tom L. Blundell, Carlos H. M. Rodrigues, T.L. Blundell, Yoochan Myung, Raquel C. de Melo-Minardi, Wagner Meira, Carlos Henrique da Silveira, Stephanie Portelli and Alex G. C. de Sá. Their work appears in journals such as Nucleic Acids Research, Bioinformatics, Briefings in Bioinformatics, Scientific Reports and Journal of Chemical Information and Modeling.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact